{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:34:25Z","timestamp":1792791265150,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Intramural Research Programs of the National Center for Advancing Translational Sciences, National Institutes of Health","id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Viral genome sequencing provides valuable information for antiviral development, yet its integration with machine learning for virtual screening remains underexplored. To bridge this gap, viral genome sequences were combined with structural data of approved and investigational antivirals to identify virus-selective agents. In parallel, quantitative structure-activity relationship (QSAR) models were built to predict pan-antivirals. Robust models were generated with the area under the receiver operating characteristic curve (AUC-ROC)\u2009&gt;0.72 for virus-selective and &gt;0.79 for pan-antiviral predictions. These models were applied to virtually screen ~360\u2009K compounds for anti-SARS-CoV-2 activity. The 346 compounds identified by the models were tested using two in vitro assays, yielding hit rates of 9.4% (24\/256) in the pseudotyped particle (PP) entry assay and 37% (47\/128) in the RNA-dependent RNA polymerase (RdRp) assay. The top compounds showed potencies around 1\u2009\u00b5M. This study provides a framework for virtual screening of virus-selective and pan- antivirals against emerging pathogens.<\/jats:p>","DOI":"10.1038\/s42004-025-01583-2","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:57:24Z","timestamp":1750420644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Leveraging viral genome sequences and machine learning models for identification of potentially selective antiviral agents"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6430-3500","authenticated-orcid":false,"given":"Tuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-9158","authenticated-orcid":false,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-6553","authenticated-orcid":false,"given":"Catherine Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1034-0757","authenticated-orcid":false,"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8886-8311","authenticated-orcid":false,"given":"Ruili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","volume":"182","author":"DM Morens","year":"2020","unstructured":"Morens, D. M. & Fauci, A. S. Emerging pandemic diseases: how we got to COVID-19. Cell 182, 1077\u20131092 (2020).","journal-title":"Cell"},{"key":"1583_CR2","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1056\/NEJMp2003762","volume":"382","author":"B Gates","year":"2020","unstructured":"Gates, B. Responding to Covid-19\u2014a once-in-a-century pandemic? N. Engl. J. Med. 382, 1677\u20131679 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1583_CR3","unstructured":"Madhav, N. et al. Disease Control Priorities: Improving Health and Reducing Poverty (eds Mock, C. N. et al.) Ch. 17 (World Bank Publications, 2017)."},{"key":"1583_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02476-6","volume":"13","author":"A Faramarzi","year":"2024","unstructured":"Faramarzi, A. et al. The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis. Syst. Rev. 13, 68 (2024).","journal-title":"Syst. Rev."},{"key":"1583_CR5","unstructured":"Organization, W. H. WHO coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int (2024)."},{"key":"1583_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter, D. S., Jordan, M. R., Bertagnolio, S. & Shafer, R. W. HIV-1 drug resistance and resistance testing. Infect. Genet. Evol. 46, 292\u2013307 (2016).","journal-title":"Infect. Genet. Evol."},{"key":"1583_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/cbdd.12870","volume":"89","author":"M Balmith","year":"2017","unstructured":"Balmith, M., Faya, M. & Soliman, M. E. Ebola virus: a gap in drug design and discovery\u2010experimental and computational perspective. Chem. Biol. Drug Des. 89, 297\u2013308 (2017).","journal-title":"Chem. Biol. Drug Des."},{"key":"1583_CR8","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1017\/S0950268819000086","volume":"147","author":"M Shariff","year":"2019","unstructured":"Shariff, M. Nipah virus infection: a review. Epidemiol. Infect. 147, e95 (2019).","journal-title":"Epidemiol. Infect."},{"key":"1583_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239\u20131249 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"1583_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.drudis.2014.10.012","volume":"20","author":"A Lavecchia","year":"2015","unstructured":"Lavecchia, A. Machine-learning approaches in drug discovery: methods and applications. Drug Discov. Today 20, 318\u2013331 (2015).","journal-title":"Drug Discov. Today"},{"key":"1583_CR11","unstructured":"Yasir, M., Tripathi, A. S., Tripathi, M. K., Shukla, P. & Maurya, R. K. in CADD and Informatics in Drug Discovery (eds Rudrapal, M. & Khan, J.) (Springer, 2023)."},{"key":"1583_CR12","doi-asserted-by":"publisher","first-page":"198022","DOI":"10.1016\/j.virusres.2020.198022","volume":"285","author":"AT Onawole","year":"2020","unstructured":"Onawole, A. T., Sulaiman, K. O., Kolapo, T. U., Akinde, F. O. & Adegoke, R. O. COVID-19: CADD to the rescue. Virus Res. 285, 198022 (2020).","journal-title":"Virus Res."},{"key":"1583_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","volume":"18","author":"J Vamathevan","year":"2019","unstructured":"Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463\u2013477 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1583_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s42256-021-00335-w","volume":"3","author":"GB Kc","year":"2021","unstructured":"Kc, G. B. et al. A machine learning platform to estimate anti-SARS-CoV-2 activities. Nat. Mach. Intell. 3, 527\u2013535 (2021).","journal-title":"Nat. Mach. Intell."},{"key":"1583_CR15","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1021\/acs.jmedchem.1c01372","volume":"65","author":"T Xu","year":"2022","unstructured":"Xu, T. et al. Efficient identification of anti-SARS-CoV-2 compounds using chemical structure-and biological activity-based modeling. J. Med. Chem. 65, 4590\u20134599 (2022).","journal-title":"J. Med. Chem."},{"key":"1583_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41587-021-00839-1","volume":"39","author":"R Huang","year":"2021","unstructured":"Huang, R. et al. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nat. Biotechnol. 39, 747\u2013753 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1583_CR17","doi-asserted-by":"publisher","first-page":"18477","DOI":"10.1073\/pnas.2000585117","volume":"117","author":"YO Adeshina","year":"2020","unstructured":"Adeshina, Y. O., Deeds, E. J. & Karanicolas, J. Machine learning classification can reduce false positives in structure-based virtual screening. Proc. Natl Acad. Sci. USA. 117, 18477\u201318488 (2020).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"1583_CR18","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.drudis.2017.08.010","volume":"22","author":"L Zhang","year":"2017","unstructured":"Zhang, L., Tan, J., Han, D. & Zhu, H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov. Today 22, 1680\u20131685 (2017).","journal-title":"Drug Discov. Today"},{"key":"1583_CR19","doi-asserted-by":"publisher","first-page":"e1008873","DOI":"10.1371\/journal.pcbi.1008873","volume":"17","author":"L Blassel","year":"2021","unstructured":"Blassel, L. et al. Using machine learning and big data to explore the drug resistance landscape in HIV. PLoS Comput. Biol. 17, e1008873 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"1583_CR20","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1093\/bioinformatics\/btz418","volume":"35","author":"X Zeng","year":"2019","unstructured":"Zeng, X. et al. deepDR: a network-based deep learning approach to in silico drug repositioning. Bioinformatics 35, 5191\u20135198 (2019).","journal-title":"Bioinformatics"},{"key":"1583_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","volume":"16","author":"VN Petrova","year":"2018","unstructured":"Petrova, V. N. & Russell, C. A. The evolution of seasonal influenza viruses. Nat. Rev. Microbiol. 16, 47\u201360 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"1583_CR22","doi-asserted-by":"crossref","unstructured":"Angioni, R. et al. RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity. Cell Rep. Med. 4, 101266 (2023).","DOI":"10.1016\/j.xcrm.2023.101266"},{"key":"1583_CR23","doi-asserted-by":"crossref","unstructured":"Karim, M., Lo, C.-W. & Einav, S. Preparing for the next viral threat with broad-spectrum antivirals. J. Clin. Invest. 133, e170236 (2023).","DOI":"10.1172\/JCI170236"},{"key":"1583_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coviro.2021.11.003","volume":"52","author":"AE Gorbalenya","year":"2022","unstructured":"Gorbalenya, A. E. & Lauber, C. Bioinformatics of virus taxonomy: foundations and tools for developing sequence-based hierarchical classification. Curr. Opin. Virol. 52, 48\u201356 (2022).","journal-title":"Curr. Opin. Virol."},{"key":"1583_CR25","doi-asserted-by":"publisher","first-page":"107945","DOI":"10.1016\/j.asoc.2021.107945","volume":"113","author":"K Deepthi","year":"2021","unstructured":"Deepthi, K., Jereesh, A. & Liu, Y. A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing. Appl. Soft Comput. 113, 107945 (2021).","journal-title":"Appl. Soft Comput."},{"key":"1583_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrmicro3475","volume":"13","author":"F Vigant","year":"2015","unstructured":"Vigant, F., Santos, N. C. & Lee, B. Broad-spectrum antivirals against viral fusion. Nat. Rev. Microbiol. 13, 426\u2013437 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"1583_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","volume":"24","author":"L Strasfeld","year":"2010","unstructured":"Strasfeld, L. & Chou, S. Antiviral drug resistance: mechanisms and clinical implications. Infect. Dis. Clin. North Am. 24, 413\u2013437 (2010).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"1583_CR28","unstructured":"Xu, T., Xia, M. & Huang, R. in Machine Learning and Deep Learning in Computational Toxicology (ed. Hong, H.) Ch. 19 (Springer, 2023)."},{"key":"1583_CR29","doi-asserted-by":"publisher","first-page":"32119","DOI":"10.1021\/acsomega.2c03363","volume":"7","author":"A Speck-Planche","year":"2022","unstructured":"Speck-Planche, A. & Kleandrova, V. V. Multi-condition QSAR model for the virtual design of chemicals with dual pan-antiviral and anti-cytokine storm profiles. ACS omega 7, 32119\u201332130 (2022).","journal-title":"ACS omega"},{"key":"1583_CR30","doi-asserted-by":"publisher","first-page":"204020661876129","DOI":"10.1177\/2040206618761299","volume":"26","author":"L Eyer","year":"2018","unstructured":"Eyer, L. et al. Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antivir. Chem. Chemother. 26, 2040206618761299 (2018).","journal-title":"Antivir. Chem. Chemother."},{"key":"1583_CR31","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1016\/j.bmc.2007.04.032","volume":"15","author":"K Star\u010devi\u0107","year":"2007","unstructured":"Star\u010devi\u0107, K. et al. Synthesis, antiviral and antitumor activity of 2-substituted-5-amidino-benzimidazoles. Bioorg. Med. Chem. 15, 4419\u20134426 (2007).","journal-title":"Bioorg. Med. Chem."},{"key":"1583_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/ph14090893","volume":"14","author":"MDCAD Bianco","year":"2021","unstructured":"Bianco, M. D. C. A. D., Marinho, D. I. L. F., Hoelz, L. V. B., Bastos, M. M. & Boechat, N. Pyrroles as privileged scaffolds in the search for new potential HIV inhibitors. Pharmaceuticals 14, 893 (2021).","journal-title":"Pharmaceuticals"},{"key":"1583_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent, M. J. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 1\u201310 (2005).","journal-title":"Virol. J."},{"key":"1583_CR34","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1039\/D1MD00247C","volume":"12","author":"B Bai","year":"2021","unstructured":"Bai, B. et al. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. RSC Med. Chem. 12, 1722\u20131730 (2021).","journal-title":"RSC Med. Chem."},{"key":"1583_CR35","unstructured":"Paintsil, E. & Cheng, Y.-C. Antiviral agents. Encyclopedia Microbiol. 176\u2013225 (2019)."},{"key":"1583_CR36","unstructured":"Xu, T., Ngan, D. K. & Huang, R. in QSAR in Safety Evaluation and Risk Assessment (ed. Hong, H.) Ch. 18 (Elsevier, 2024)."},{"key":"1583_CR37","doi-asserted-by":"crossref","unstructured":"Hasan, M. K. et al. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: a computational hierarchical investigation. Heliyon 7, e06435 (2021).","DOI":"10.1016\/j.heliyon.2021.e06435"},{"key":"1583_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-199716010-00001","volume":"16","author":"M Levy","year":"1997","unstructured":"Levy, M. Role of viral infections in the induction of adverse drug reactions. Drug Saf. 16, 1\u20138 (1997).","journal-title":"Drug Saf."},{"key":"1583_CR39","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.3390\/molecules28207204","volume":"28","author":"F Carvalhal","year":"2023","unstructured":"Carvalhal, F. et al. Evaluation of the cytotoxic and antiviral effects of small molecules selected by in silico studies as inhibitors of SARS-CoV-2 cell entry. Molecules 28, 7204 (2023).","journal-title":"Molecules"},{"key":"1583_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41392-023-01580-8","volume":"8","author":"C Yuan","year":"2023","unstructured":"Yuan, C. et al. The role of cell death in SARS-CoV-2 infection. Signal Transduct. Target. Ther. 8, 357 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1583_CR41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.drudis.2021.05.012","volume":"26","author":"T Xu","year":"2021","unstructured":"Xu, T., Zheng, W. & Huang, R. High\u2010throughput screening assays for SARS\u2010CoV\u20102 drug development: current status and future directions. Drug Discov. Today 26, 2439\u20132444 (2021).","journal-title":"Drug Discov. Today"},{"key":"1583_CR42","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."},{"key":"1583_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.slasd.2021.12.005","volume":"27","author":"M Xu","year":"2022","unstructured":"Xu, M. et al. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discov. 27, 86\u201394 (2022).","journal-title":"SLAS Discov."},{"key":"1583_CR44","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1016\/j.bmcl.2007.08.027","volume":"17","author":"P Cheng","year":"2007","unstructured":"Cheng, P. et al. Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. Bioorg. Med. Chem. Lett. 17, 5316\u20135320 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1583_CR45","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/2472555220942123","volume":"25","author":"W Zhu","year":"2020","unstructured":"Zhu, W. et al. RNA-dependent RNA polymerase as a target for COVID-19 drug discovery. SLAS Discov. 25, 1141\u20131151 (2020).","journal-title":"SLAS Discov."},{"key":"1583_CR46","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.tranon.2018.11.016","volume":"12","author":"K Gorshkov","year":"2019","unstructured":"Gorshkov, K. et al. Quantitative chemotherapeutic profiling of gynecologic cancer cell lines using approved drugs and bioactive compounds. Transl. Oncol. 12, 441\u2013452 (2019).","journal-title":"Transl. Oncol."},{"key":"1583_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-0716-2213-1_13","volume":"2474","author":"R Huang","year":"2022","unstructured":"Huang, R. A quantitative high-throughput screening data analysis pipeline for activity profiling. Methods Mol. Biol. 2474, 133\u2013145 (2022).","journal-title":"Methods Mol. Biol."},{"key":"1583_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1021\/acs.chemrestox.9b00305","volume":"33","author":"T Xu","year":"2020","unstructured":"Xu, T. et al. Predictive models for human organ toxicity based on in vitro bioactivity data and chemical structure. Chem. Res. Toxicol. 33, 731\u2013741 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"1583_CR49","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/acs.chemrestox.0c00305","volume":"34","author":"T Xu","year":"2020","unstructured":"Xu, T., Wu, L., Xia, M., Simeonov, A. & Huang, R. Systematic identification of molecular targets and pathways related to human organ level toxicity. Chem. Res. Toxicol. 34, 412\u2013421 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"1583_CR50","doi-asserted-by":"publisher","first-page":"116250","DOI":"10.1016\/j.taap.2022.116250","volume":"454","author":"L Ye","year":"2022","unstructured":"Ye, L. et al. Prediction of drug-induced liver injury and cardiotoxicity using chemical structure and in vitro assay data. Toxicol. Appl. Pharmacol. 454, 116250 (2022).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1583_CR51","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acs.jcim.3c00230","volume":"63","author":"T Xu","year":"2023","unstructured":"Xu, T. et al. Identification of potent and selective acetylcholinesterase\/butyrylcholinesterase inhibitors by virtual screening. J. Chem. Inf. Model. 63, 2321\u20132330 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"1583_CR52","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1021\/acs.jcim.2c01516","volume":"63","author":"T Xu","year":"2023","unstructured":"Xu, T. et al. Predictive models for human cytochrome P450 3A7 selective inhibitors and substrates. J. Chem. Inf. Model. 63, 846\u2013855 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"1583_CR53","doi-asserted-by":"publisher","first-page":"1321857","DOI":"10.3389\/ftox.2024.1321857","volume":"6","author":"Z Wei","year":"2024","unstructured":"Wei, Z. et al. Use of in vitro methods combined with in silico analysis to identify potential skin sensitizers in the Tox21 10K compound library. Front. Toxicol. 6, 1321857 (2024).","journal-title":"Front. Toxicol."}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01583-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01583-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01583-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:02:52Z","timestamp":1750424572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01583-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1038\/s42004-025-01583-2","relation":{},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}